According to the results of a single-center, prospective, crossover study, darbepoetin alfa—a hyperglycosylated, and therefore longer-acting, derivative of epoetin—is a more effective ...

Purpose: The effectiveness of every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia was evaluated. Methods: Women receiving chemotherapy for ...

Purpose: The cost of darbepoetin alfa versus that of epoetin alfa in a hospital setting was studied. Methods: The study was an observational, retrospective review of the hospitalwide use of ...

When he worked for the California-based biotechnology company Amgen in the 1990s, Steve Elliott was instrumental in the development of darbepoetin alfa (Aranesp), a drug to treat anemia in people with ...

Darbepoetin alfa 10mcg/0.4mL, 25mcg/0.42mL, 40mcg/0.4mL, 60mcg/0.3mL, 100mcg/0.5mL, 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/mL; per prefilled syringe; for IV ...

MBV already has a candidate drug in phase 1, MK2578 (pegylated erythropoietin), designed to compete with Thousand Oaks, California–based Amgen's Aranesp (darbepoetin alfa), and at least five ...